BIOMAT Database Logo BIOMAT Database Logo

Follow-up of subjects with isolated and persistent anti-core (anti-p24 or anti-p17) antibodies to HIV. 1988

J J Lefrère, and A M Couroucé, and G Lucotte, and C Boitard, and C Kaplan, and J C Nicolas, and F Bricout, and P Lambin, and C Doinel, and J Y Muller
Institut National de Transfusion Sanguine, Paris, France.

Systematic screening of blood donations by enzyme-linked immunosorbent assay (ELISA) for HIV antibodies carries a false-positive rate: the sera involved react in Western blot to core antigens (p24 or p17) but reactivity to envelope is absent. We studied 22 subjects with persistent and isolated anti-core reactivities; 75 HIV seropositive patients were controls. The epidemiological data and the follow-up and biological tests performed in these two populations argue that donors with persistent and isolated anti-core antibodies are not seroconverting for HIV. We conclude: (1) that verification of all anti-HIV ELISA-positive sera by Western blot is essential and that the presence of at least once anti-envelope (gp120 or gp41) antibody is indispensable for the diagnosis of HIV infection; (2) that the solitary anti-p24 or anti-p17 bands observed on Western blot are false-positive. There is no evidence that donors with such reactivities are HIV-infected.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001782 Blood Donors Individuals supplying blood or blood components for transfer to histocompatible recipients. Blood Donor,Donor, Blood,Donors, Blood
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D005189 False Positive Reactions Positive test results in subjects who do not possess the attribute for which the test is conducted. The labeling of healthy persons as diseased when screening in the detection of disease. (Last, A Dictionary of Epidemiology, 2d ed) False Positive Reaction,Positive Reaction, False,Positive Reactions, False,Reaction, False Positive,Reactions, False Positive
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006678 HIV Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2. AIDS Virus,HTLV-III,Human Immunodeficiency Viruses,Human T-Cell Lymphotropic Virus Type III,Human T-Lymphotropic Virus Type III,LAV-HTLV-III,Lymphadenopathy-Associated Virus,Acquired Immune Deficiency Syndrome Virus,Acquired Immunodeficiency Syndrome Virus,Human Immunodeficiency Virus,Human T Cell Lymphotropic Virus Type III,Human T Lymphotropic Virus Type III,Human T-Cell Leukemia Virus Type III,Immunodeficiency Virus, Human,Immunodeficiency Viruses, Human,Virus, Human Immunodeficiency,Viruses, Human Immunodeficiency,AIDS Viruses,Human T Cell Leukemia Virus Type III,Lymphadenopathy Associated Virus,Lymphadenopathy-Associated Viruses,Virus, AIDS,Virus, Lymphadenopathy-Associated,Viruses, AIDS,Viruses, Lymphadenopathy-Associated
D006800 Deltaretrovirus Infections Infections caused by the HTLV or BLV deltaretroviruses. They include human T-cell leukemia-lymphoma (LEUKEMIA-LYMPHOMA, T-CELL, ACUTE, HTLV-I-ASSOCIATED). BLV Infections,HTLV Infections,HTLV-BLV Infections,BLV Infection,Deltaretrovirus Infection,HTLV BLV Infections,HTLV Infection,HTLV-BLV Infection,Infection, Deltaretrovirus,Infections, Deltaretrovirus
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

J J Lefrère, and A M Couroucé, and G Lucotte, and C Boitard, and C Kaplan, and J C Nicolas, and F Bricout, and P Lambin, and C Doinel, and J Y Muller
[Follow-up of blood donors with indeterminate reaction to anti-HIV 1/2 EIA or isolated detection of antibodies to HIV-1 core antigens (anti-p24)].
January 1992, Beitrage zur Infusionstherapie = Contributions to infusion therapy,
J J Lefrère, and A M Couroucé, and G Lucotte, and C Boitard, and C Kaplan, and J C Nicolas, and F Bricout, and P Lambin, and C Doinel, and J Y Muller
Failure to detect evidence of human immunodeficiency virus type 1 (HIV-1) infection by polymerase chain reaction assay in blood donors with isolated core antibodies (anti-p24 or -p17) to HIV-1.
October 1990, Transfusion,
J J Lefrère, and A M Couroucé, and G Lucotte, and C Boitard, and C Kaplan, and J C Nicolas, and F Bricout, and P Lambin, and C Doinel, and J Y Muller
Differential maturation of avidity of IgG antibodies to gp41, p24 and p17 following infection with HIV-1.
February 1996, Clinical and experimental immunology,
J J Lefrère, and A M Couroucé, and G Lucotte, and C Boitard, and C Kaplan, and J C Nicolas, and F Bricout, and P Lambin, and C Doinel, and J Y Muller
Clinical and laboratory follow-up of asymptomatic blood donors with only anti-HIV 'core' antibodies.
January 1988, Vox sanguinis,
J J Lefrère, and A M Couroucé, and G Lucotte, and C Boitard, and C Kaplan, and J C Nicolas, and F Bricout, and P Lambin, and C Doinel, and J Y Muller
Immunodominant epitopes of HIV-1 p17 and p24.
October 1992, AIDS research and human retroviruses,
J J Lefrère, and A M Couroucé, and G Lucotte, and C Boitard, and C Kaplan, and J C Nicolas, and F Bricout, and P Lambin, and C Doinel, and J Y Muller
Specificity of binding of HIV-1 anti-p24 antibodies to CD4+ lymphocytes from HIV-infected subjects.
September 1998, Cytometry,
J J Lefrère, and A M Couroucé, and G Lucotte, and C Boitard, and C Kaplan, and J C Nicolas, and F Bricout, and P Lambin, and C Doinel, and J Y Muller
A pilot phase II study of the safety and immunogenicity of HIV p17/p24:VLP (p24-VLP) in asymptomatic HIV seropositive subjects.
November 1997, The Journal of infection,
J J Lefrère, and A M Couroucé, and G Lucotte, and C Boitard, and C Kaplan, and J C Nicolas, and F Bricout, and P Lambin, and C Doinel, and J Y Muller
Long-term follow-up: no effect of therapeutic vaccination with HIV-1 p17/p24:Ty virus-like particles on HIV-1 disease progression.
May 2002, Vaccine,
J J Lefrère, and A M Couroucé, and G Lucotte, and C Boitard, and C Kaplan, and J C Nicolas, and F Bricout, and P Lambin, and C Doinel, and J Y Muller
The affinity of IgG antibodies to gag p24 and p17 in HIV-1-infected patients correlates with disease progression.
February 1995, Clinical and experimental immunology,
J J Lefrère, and A M Couroucé, and G Lucotte, and C Boitard, and C Kaplan, and J C Nicolas, and F Bricout, and P Lambin, and C Doinel, and J Y Muller
[Expression and characterization of HIV-1 Gag p17-p24 protein].
January 2000, Sheng wu gong cheng xue bao = Chinese journal of biotechnology,
Copied contents to your clipboard!